Phase 4
Completed N=18
Rejuvenation of the Lower Eyelid Using a Combination of Two Hyaluronic Acid Fillers - a Pilot Study
Infraorbital Hollows
Source: ClinicalTrials.gov NCT00852241 ↗
Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Mar 2018
Primary outcomePrimary: The Primary Objective of This Study is to Determine the Efficacy and Longevity of the Use of Restylane® and Perlane® in Combination for the Rejuvenation of the Infraorbital Hollows and to Measure Patient Satisfaction With This Treatment
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The primary objective of this study is to determine the efficacy and longevity of the use of Restylane® and Perlane® in combination for the rejuvenation of the infraorbital hollows and to measure patient satisfaction with this treatment
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Primary Objective of This Study is to Determine the Efficacy and Longevity of the Use of Restylane® and Perlane® in Combination for the Rejuvenation of the Infraorbital Hollows and to Measure Patient Satisfaction With This Treatment |
— | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 years and older
- No significant medical illness
- Subjects with the willingness and ability to understand and provide informed consent
Exclusion Criteria
- Under 18 years of age
- Pregnancy or Lactation
- Subjects who have had previous surgical treatment of the lower eyelid area or previous use of filling agents in the under eye area
- Subjects with a known allergy to the components in Restylane® or Perlane®
- Subjects currently taking blood thinners or who have had chemotherapy or radiation within the last 6 months
- Subjects with liver/kidney disease or compromise or who are immunocompromised
- Subjects with a known susceptibility to keloid formation or hypertrophic scarring
- Subjects with an open, non-healing sore or infection near the site of injections
- Subjects who are unable to understand the protocol or to give informed consent
- Subjects with mental illness
Data sourced from ClinicalTrials.gov (NCT00852241). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.